QSM Asset Management Ltd Buys 46,100 Shares of Pfizer Inc. $PFE

QSM Asset Management Ltd boosted its position in Pfizer Inc. (NYSE:PFE) by 10.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 506,843 shares of the biopharmaceutical company’s stock after purchasing an additional 46,100 shares during the quarter. Pfizer comprises approximately 7.2% of QSM Asset Management Ltd’s investment portfolio, making the stock its 4th biggest holding. QSM Asset Management Ltd’s holdings in Pfizer were worth $12,620,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares in the last quarter. Grey Fox Wealth Advisors LLC bought a new position in Pfizer during the third quarter valued at about $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the second quarter valued at about $30,000. True Wealth Design LLC grew its holdings in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the period. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer during the second quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. Barclays initiated coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Stock Up 2.6%

PFE stock opened at $27.75 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $157.80 billion, a P/E ratio of 20.41 and a beta of 0.47. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company’s 50 day simple moving average is $26.88 and its 200-day simple moving average is $25.72.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the company posted $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Market optimism around Pfizer’s once‑monthly GLP‑1/weight‑loss candidate and coverage by high‑profile commentators has driven short‑term buying interest — investors are revisiting Pfizer’s positioning in the obesity/GLP‑1 market. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Longer‑term bullish commentary and retail coverage argue Pfizer’s diversified portfolio, pipeline and ability to pivot (including GLP‑1 work) make it an attractive buy for patient investors. This kind of coverage can sustain inflows beyond short‑term headlines. Prediction: Buying Pfizer Stock Today Could Set You Up for Life
• Positive Sentiment: Inclusion on lists of large‑cap stocks with high dividends highlights Pfizer’s income appeal; dividend support can attract conservative and yield‑seeking investors amid growth uncertainty. Pfizer (PFE) – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Spike in search and retail attention (tracked by Zacks) signals higher visibility and trading volume; increased attention can amplify moves in either direction depending on upcoming catalysts. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Consensus analyst rating remains a “Hold” (mixed buy/hold/sell split), reflecting balanced views on near‑term growth vs. pipeline uncertainty — this limits the likelihood of broad upgrades unless clinical or commercial news surprises to the upside. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Competitive moves from rivals — notably Eli Lilly’s large AI‑enabled drug discovery deal — underline accelerating competition and faster innovation cycles in diabetes/weight‑loss and other areas, a risk to Pfizer’s market share and margin outlook over time. Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.